 Connection
David Riches to Bridged Bicyclo Compounds, Heterocyclic
This is a "connection" page, showing publications David Riches has written about Bridged Bicyclo Compounds, Heterocyclic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.407 |
|
|
|
-
Cooley JC, Penick SK, Wilson JA, Javkhlan N, Foster DG, Edelman BL, Schott CA, Humphries SM, Lynch DA, Schwartz DA, Riches DWH, Redente EF. Nintedanib increases BCL-2 in fibrotic fibroblasts, enhancing ABT-199 apoptosis and fibrosis resolution. Am J Respir Cell Mol Biol. 2026 Aug 01; 74(8):1103-1113.
Score: 0.207
-
Redente EF, Song T, Javkhlan N, Edelman BL, Foster DG, Wilson JA, Chakraborty S, Cooley JC, Gaurav R, Saguthi S, Seibold MA, Blumhagen RZ, Schwartz DA, Yang IV, Matsuda J, Bridges JP, Zemans RL, Tuder RM, Riches DWH. Conditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition. Nat Commun. 2026 Feb 28; 17(1).
Score: 0.201
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|